Material for Treatment of Cerebral Infarction

Abstract

A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal.

That which is claimed: 
     
         1 . A material for treating cerebral infarction comprising at least one of: a dental pulp stem cells comprising CD105-positive cells fractionated from human dental pulp stem cell populations; and culture supernatants comprising a secretory protein from CD105-positive cells fractionated from human dental pulp cell populations, into a target animal undergoing treatment for improving brain function, thereby regenerating the central nervous tissue attic brain to recover brain function. 
     
     
         2 . The material according to  claim 1 , wherein the CD105-positive cells expresses a factor comprising at least one of a cell migration factor, a cell growth factor, an angiogenic factor, and a neurotrophic factor in a peri-infarct region of the brain. 
     
     
         3 . The material according to  claim 1 , wherein the CD105-positive cells are injected at a concentration of 1×10 5  cells/μl to 1×10 7  cells/μl. 
     
     
         4 . The material according to  claim 1 , wherein the CD105-positive cells are derived from a permanent tooth or a deciduous tooth. 
     
     
         5 . The material according to  claim 2 , wherein the cell migration factor is at least one of SDF1, GCSF, MMP3, Slit, and GMCSF. 
     
     
         6 . The material according to  claim 2 , wherein the neurotrophic factor is at least one of VEGF, NGF, GDNF, BDNF, LIF, MYC, Neurotrophine 3, TP53, and BAX. 
     
     
         7 . The material according to  claim 2 , wherein the cell growth factor is at least one of bFGF and PDGF. 
     
     
         8 . The material according to  claim 3 , wherein the angiogenic factor is at least one of PGF, CXCL1, CXCL2, CXCL3, CXCI,5, CXCL10, ANPEP, NRP1, TGFβ, ECGF1, ID1, and CSF3. 
     
     
         9 . The material according to  claim 1 , wherein the CD105-positive cells are cryopreserved cells. 
     
     
         10 . The material according to  claim 1 , wherein the CD105-positive cells are autologous cells. 
     
     
         11 . The material according to  claim 1 , wherein the CD105-positive cells are allogenic cells or xenogenic cells. 
     
     
         12 . The material according to  claim 1 , wherein the method comprises injecting at least one of: dental pulp cells consisting essentially of CD105-positive cells fractionated from human dental pulp stem cell populations; and culture supernatants comprising a secretory protein from CD105-positive cells fractionated from human dental pulp cell populations.